These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 618707)

  • 1. Determination of procainamide acetylator status.
    Lima JJ; Jusko WJ
    Clin Pharmacol Ther; 1978 Jan; 23(1):25-9. PubMed ID: 618707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic acetylation procainamide in man.
    Reidenberg MM; Drayer DE; Levy M; Warner H
    Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of slow-release procainamide.
    Tilstone WJ; Lawson DH; Campbell W; Hutton I; Lawrie TD
    Eur J Clin Pharmacol; 1978 Dec; 14(4):261-5. PubMed ID: 729620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the acetylation of procainamide and sulfadimidine in man.
    Frislid K; Berg M; Hansteen V; Lunde PK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):433-8. PubMed ID: 971707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.
    Coyle JD; Boudoulas H; Lima JJ
    Biopharm Drug Dispos; 1991 Nov; 12(8):599-612. PubMed ID: 1724922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capacity-limited elimination of procainamide in man.
    Tilstone WJ; Lawson DH
    Res Commun Chem Pathol Pharmacol; 1978 Aug; 21(2):343-6. PubMed ID: 694230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.
    Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA
    Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway.
    Schneck DW; Sprouse JS; Shiroff RA; Vary JE; DeWitt FO; Hayes AH
    Pharmacology; 1979; 18(1):34-41. PubMed ID: 419159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
    Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA
    N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between the metabolism of procainamide and sulfamethazine.
    Giardina E-GV ; Stein RM; Bigger JT
    Circulation; 1977 Feb; 55(2):388-94. PubMed ID: 832354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.
    Lima JJ; Conti DR; Goldfarb AL; Tilstone WJ; Golden LH; Jusko WJ
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):69-85. PubMed ID: 458558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethanol-induced increase in procainamide acetylation in man.
    Olsen H; Mørland J
    Br J Clin Pharmacol; 1982 Feb; 13(2):203-8. PubMed ID: 7059417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic approach to intravenous procainamide therapy.
    Lima JJ; Conti DR; Goldfarb AL; Golden LH; Jusko WJ
    Eur J Clin Pharmacol; 1978 Jun; 13(4):303-8. PubMed ID: 668789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of procainamide and N-acetylprocainamide in renal failure.
    Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA
    Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the acetylation phenotype and the therapeutic effect of procainamide.
    Schröder P; Klitgaard NA; Simonsen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of exercise on plasma levels and urinary excretion of sulphadimidine and procainamide.
    Ylitalo P; Hinkka H
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):548-53. PubMed ID: 4066079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethanol interaction with drug acetylation in vivo and in vitro.
    Olsen H; Mørland J
    Pharmacol Biochem Behav; 1983; 18 Suppl 1():295-300. PubMed ID: 6634843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.